GSK’s check­point block­er Jem­per­li cures bio­mark­er-dri­ven rec­tal can­cer

GSK’s Jem­per­li has main­tained its out­stand­ing ef­fi­ca­cy among pa­tients with a par­tic­u­lar form of rec­tal can­cer. Every one of 49 pa­tients with mis­match re­pair de­fi­cient …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER